在其他近期新闻中，Immunovant受到多个分析师更新和公司发展的关注。Guggenheim Securities将Immunovant股票的目标价从46美元下调至44美元，同时维持买入评级。该公司预计Immunovant在治疗重症肌无力和慢性炎症性脱髓鞘性多发性神经病方面的batoclimab临床试验将取得重要结果。同时，H.C.

Q4 and is likely to become significantly profitable and cash flow positive in 2025. Read my analysis on ARGX stock here.

根据提交给证券交易委员会的Form 4文件显示，Immunovant, Inc.（NASDAQ:IMVT）首席医疗官William L. Macias于2025年2月19日以每股20.86美元的加权平均价格出售了2,055股公司股票，交易总额约为42,867美元。目前该股票交易价格为21.27美元，获得分析师的强烈关注，整体评级看涨。 InvestingPro ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...

Immunovant, Inc. (IMVT) has been on a downward spiral lately with significant selling pressure. After declining 15.5% over the past four weeks, the stock looks well positioned for a trend reversal as ...

In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immunovant (IMVT – Research Report), Summit Therapeutics ...

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Immunovant (IMVT – Research Report), with a price ...